KDR and cancer: Other examples were done using the single structural templates for the design of VHH focusing on several targets: vascular endothelial growth factor receptor 2 (VEGFR2) for antiangiogenic strategies in cancer therapy [116], bone morphogenic factor 4 (BMP4, implicated in carcinogenesis and tumour progression [117]), CD47 molecule, a promising cancer biomarker [118] and Vascular Endothelial Growth Factor 165 implicated in tumour angiogenesis and metastasis [119].